Ranibizumab for Myopic Neovascularization

• Status: Unknown status
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Instituto de Olhos de Goiania
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Myopic and CNVM

Exclusion Criteria:

• Patients with poor compliance

• Patients with uncontrolled diabetes and hypertension or any other medical condition that increase the risk of complications like recent history of Stroke or myocardial infraction (< one year). (Physician clearance was obtained for all patients).

• Age related macular degeneration with Juxtafoveal and Subfoveal CNVM: Recurrent CNVM following PDT and TTT with IVTA. Patient who could not afford PDT, Macugen or Lucentis which is FDA approved.

• Patients who had undergone major surgery 28 days before, were excluded from the study and it was also suspended prior to elective surgery.

• Refractory macular oedema due to vein occlusion, Pseudophakia, Clinically significant macular oedema (CSME) etc. that affects vision and does not respond adequately to usual treatment methods.

• Proliferative diabetic retinopathy, non-resolving vitreous haemorrhage with PDR.

• Idiopathic CNVM, Inflammatory CNVM and other conditions associated with CNVM.